UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF CASH FLOW (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Net income	$ 10,169	$ 7,414	$ 6,014
Depreciation	653	707	563
Amortization	2,613	2,066	44
(Gain) loss on investments	177	(6)	(38)
Provision for (recovery of) losses on accounts receivable	5	77	6
Loss on disposal of assets			0
Deferred income taxes	(600)	(549)
Stock-based compensation expense	70	95	83
(Increase) decrease in accounts receivable	675	502	110
(Increase) decrease in accrued interest and other receivables	(204)	(31)	(165)
(Increase) decrease in inventories	841	(624)	286
(Increase) decrease in prepaid expenses and other current assets	(125)	529	58
Increase (decrease) in accounts payable	50	(1,213)	52
Increase (decrease) in accrued expenses	(570)	2,158	143
Increase (decrease) in deferred revenue	(100)	(66)
Increase (decrease) in other liability	(91)	307
Net cash provided by operating activities	13,563	11,365	7,157
Capital expenditures for property and equipment	(254)	(247)	(1,532)
Capital expenditures for intangible assets	(1)	(10)	(2)
Purchases of investments		(500)	(1,600)
Proceeds from the sale of investments	47	15,155	5,839
Net cash paid in acquisition		(41,084)
Net cash provided by (used in) investing activities	(208)	(26,685)	2,705
Proceeds from issuance of common stock - options	1,803	485	425
Common stock purchased and retired	(504)		(439)
Tax benefit attributable to exercise of stock options	178	34	38
Proceeds from notes payable		26,934
Repayments of notes payable	(9,093)	(5,942)	(413)
Dividends paid	(3,555)	(3,433)	(6,030)
Net cash provided by (used in) financing activities	(11,171)	18,078	(6,419)
Effect of exchange rate changes on cash	153	(41)	(35)
NET INCREASE IN CASH AND CASH EQUIVALENTS	2,336	2,717	3,408
CASH AT BEGINNING OF YEAR	6,534	3,818	410
CASH AT END OF YEAR	8,871	6,534	3,818
Cash paid during the year for income taxes	4,423	2,685	2,810
Cash paid during the year for interest	$ 658	$ 860	$ 25